Furthermore, our findings of the correlation of increased expression of TRA16 with increased malignancy of NSCLC demonstrate that TRA16 could be a valuable biomarker to monitor the progression of the tumor, and provide physicians with useful information to evaluate the severity of the disease and to choose proper treatments for NSCLC patients. Here, NR2C2AP is linked to non-small cell lung carcinoma.